Trial Overview
Incyte (NASDAQ:INCY) announced results from its Phase 3 frontMIND trial, which evaluated tafasitamab plus lenalidomide combined with R‑CHOP chemotherapy as a first‑line regimen for adults with previously untreated high‑risk diffuse large B‑cell lymphoma (DLBCL) and high‑grade B‑cell lymphoma. The data were presented at the European Hematology Association 2026 Congress in Stockholm. The study enrolled 899 patients aged 18 to 80 years with an International Prognostic Index score of 3‑5.
Efficacy Results
The combination therapy reduced the risk of disease progression or death by 25% compared with R‑CHOP alone, yielding a hazard ratio of 0.75 and a p‑value of 0.0194. At two years, progression‑free survival (PFS) was 71.1% for the combination versus 62.9% for R‑CHOP alone; at three years, PFS was 67.3% versus 60.7%. Event‑free survival also improved, with a hazard ratio of 0.79. An interim overall‑survival analysis showed a hazard ratio of 0.85, which did not achieve statistical significance.
Safety Profile
The most common treatment‑emergent adverse events with the combination were neutropenia (70.7%), anemia (46.3%) and peripheral neuropathy (40.6%). Grade 3 or higher adverse events occurred in 86.7% of patients receiving the combination compared with 76.1% on R‑CHOP alone. Fatal treatment‑emergent adverse events were reported in 5.9% of combination patients versus 3.8% with R‑CHOP, while overall deaths were 18.5% versus 21.7%, respectively.
Market Reaction & Financial Highlights
Following the announcement, Incyte’s shares traded at $108.53, delivering a 60% total return over the past year. InvestingPro noted a 21% revenue growth and assigned an “EXCELLENT” financial health score, indicating the company remains undervalued relative to its fair value.
Pipeline & Corporate Developments
Tafasitamab is already approved in the United States in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma; Incyte stated that the frontMIND data support global regulatory submissions for the previously untreated patient population. In parallel, Incyte completed a $1.25 billion upfront acquisition of Vega Therapeutics, securing VGA039, a Phase 3 protein S monoclonal antibody for von Willebrand disease prophylaxis. Following the acquisition, H.C. Wainwright raised its price target to $140 (Buy), Oppenheimer to $107 (Outperform), and Stifel reiterated a Buy rating with a $123 target, citing the strategic value of VGA039. Additionally, Incyte and Mirum Pharmaceuticals plan to present Phase 2 results from the PROGRESS study on zilurgisertib at the ENDO 2026 meeting. Citizens maintained a Market Perform rating on the basis of the positive lymphoma trial outcomes.